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ABSTRACT
Objectives: The optimal method of identifying people
with chronic obstructive pulmonary disease (COPD)
from electronic primary care records is not known. We
assessed the accuracy of different approaches using
the Clinical Practice Research Datalink, a UK electronic
health record database.
Setting: 951 participants registered with a CPRD
practice in the UK between 1 January 2004 and 31
December 2012. Individuals were selected for ≥1 of 8
algorithms to identify people with COPD. General
practitioners were sent a brief questionnaire and
additional evidence to support a COPD diagnosis was
requested. All information received was reviewed
independently by two respiratory physicians whose
opinion was taken as the gold standard.
Primary outcome measure: The primary measure
of accuracy was the positive predictive value (PPV), the
proportion of people identified by each algorithm for
whom COPD was confirmed.
Results: 951 questionnaires were sent and 738 (78%)
returned. After quality control, 696 (73.2%) patients
were included in the final analysis. All four algorithms
including a specific COPD diagnostic code performed
well. Using a diagnostic code alone, the PPV was
86.5% (77.5–92.3%) while requiring a diagnosis plus
spirometry plus specific medication; the PPV was
slightly higher at 89.4% (80.7–94.5%) but reduced
case numbers by 10%. Algorithms without specific
diagnostic codes had low PPVs (range 12.2–44.4%).
Conclusions: Patients with COPD can be accurately
identified from UK primary care records using specific
diagnostic codes. Requiring spirometry or COPD
medications only marginally improved accuracy. The
high accuracy applies since the introduction of an
incentivised disease register for COPD as part of
Quality and Outcomes Framework in 2004.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) represents an enormous health
burden worldwide. Currently, COPD is the
fourth leading cause of death and is pre-
dicted to become the third by 2020.1 There
are approximately 835 000 people diagnosed
with COPD in the UK and an estimated
2 200 000 people remain undiagnosed.2 3
Electronic health records in the UK
provide an excellent resource in which to
study COPD as they offer a large cohort size,
the presence of disease severity indicators
and long-term follow-up information on a
patient’s integrated medical history.
Although multiple studies have been under-
taken to investigate various aspects of COPD
over the past 10 years in several electronic
health record databases, there is no standard
deﬁnition used to identify COPD in large
databases and codelists used to identify
patients with COPD vary by author. Over
10 years ago, the diagnosis of COPD was vali-
dated in the Clinical Practice Research
Datalink-Global initiative for Chronic
Strengths and limitations of this study
▪ We have shown that the presence of a specific
chronic obstructive pulmonary disease (COPD)
Read code alone is sufficient to identify patients
with COPD from electronic health records.
Minimal precision lost by not including spirom-
etry and medications in the algorithm allows an
increase in the number of individuals who can
potentially be included in a study by up to 10%.
▪ We were able to investigate the accuracy of algo-
rithms when identifying patients with COPD
within the CPRD, and the accuracy of the actual
general practitioner diagnosis of COPD.
▪ The amount of missing data among the respond-
ing questionnaires was low, suggesting reason-
able data quality.
▪ Although the overall response rate for this study
was acceptable (77.6%), the proportion of ques-
tionnaires accompanied by additional evidence
allowing for adjudication was lower.
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Obstructive Lung Disease (CPRD-GOLD, formerly
GPRD) using OXMIS codes.4 This coding system is now
obsolete in CPRD and Read codes are used as the
standard.
There is no single diagnostic test for COPD. The diag-
nosis of COPD relies on clinical judgement based on a
combination of history, physical examination and con-
ﬁrmation of the presence of airﬂow obstruction using
spirometry.5 When retrospectively evaluating the accur-
acy of a COPD diagnosis, commonly used COPD deﬁni-
tions may misclassify patients as having COPD. Using
multiple diagnostic codes in combination with pharmacy
may improve the accuracy of identiﬁcation of patients
with COPD.6 Further, over the past 10 years, the deﬁn-
ition of COPD in clinical practice has evolved, leading to
changes in how COPD is diagnosed and the diagnosis
recorded. With the introduction of the Quality and
Outcomes Framework (QOF) codes for COPD in 2004
in England and Wales, there are more codes available to
identify COPD then there were previously. QOF is a vol-
untary incentive scheme for primary care physicians
(general practitioners, GPs) in the UK which contains
indicators against which GP practices can score points
and hence be rewarded for how well they care for
patients.7 Evaluation of airﬂow limitation using spirom-
etry is used as the standard to conﬁrm COPD diagnosis
and severity of COPD is part of the patient with annual
COPD review.3 8 However, even spirometry, if incorrectly
performed or interpreted, can lead to misdiagnosis
(both overdiagnosis and underdiagnosis of COPD) in
approximately 20% of cases. It is also recognised that
some subgroups of individuals (eg, women and indivi-
duals under 50 and over 80) are less likely to have spir-
ometry measured.8
This study aimed to improve our ability to identify
patients with COPD within electronic health records. We
used the CPRD, a widely used collection of compu-
terised medical records, which is commonly used for
clinical and research purposes. CPRD is comparable to
other electronic health record databases used in the UK.
Our objective was to test the accuracy of different deﬁni-
tions of COPD in the CPRD using the positive predictive
value (PPV), by comparing the database records with
additional information provided by GPs. This work is
important for epidemiological research in COPD and
diseases where COPD is an important comorbidity as
well as for clinical practice.
METHODS
Data set
CPRD is the world’s largest validated computerised data-
base of anonymised longitudinal medical records for
primary care.9 10 Data comprise approximately 14
million patients with around 5.4 million of these being
currently alive and registered from 660 primary care
practices spread throughout the UK. Records are
derived from a widely used GP software system and
contain complete prescribing and coded diagnostic and
clinical information as well as information on tests
requested, laboratory results and referrals made at or
following on from each consultation.11
Codelists and algorithms
Lists of medical codes (Read codes) speciﬁc and non-
speciﬁc for COPD were created prior to the study initi-
ation. Read codes are a hierarchical clinical coding
system of over 80 000 terms that are used in general
practice in the UK and are entered by the GP into
Vision Software.12 These data are then uploaded by
CPRD after they have been processed, quality checked
and added to the CPRD database for research use.
Speciﬁc COPD codes consisted of codes listing either
COPD or COPD-speciﬁc entities of emphysema (see
online supplementary material for speciﬁc codes
included). Non-speciﬁc codes consisted of a variety of
lung diseases that could potentially be COPD, for
example, chronic bronchitis. Combinations of codelists
and additional material in the form of the presence of
spirometry or COPD medications (see online
supplementary material) were used to make up the
eight algorithms. The ﬁrst four deﬁnitions required a
speciﬁc COPD diagnosis code, with the ﬁrst three requir-
ing additional documentation (eg, medication and/or
spirometry). The other four deﬁnitions required non-
speciﬁc bronchitis or respiratory symptom codes, with
the least speciﬁc deﬁnition requiring only respiratory
symptom codes. Details regarding each algorithm can
be found in the online supplementary material. Brieﬂy,
the eight algorithms were deﬁned as follows, from the
expected most speciﬁc to most sensitive construct:
1. Speciﬁc COPD code and more than one prescription
of a COPD medication and presence of spirometry
(COPD Code+spirometry+COPD medication);
2. Speciﬁc COPD code and presence of spirometry
(COPD Code+spirometry);
3. Speciﬁc COPD code and more than one prescription
of a COPD medication (COPD Code+COPD medication)
4. Speciﬁc COPD code only (COPD Code only);
5. Non-speciﬁc bronchitis code and more than one pre-
scription of a COPD medication (Bronchitis+COPD
medication);
6. Non-speciﬁc bronchitis code only (Bronchitis only);
7. Respiratory symptoms and presence of spirometry.
Respiratory symptoms consisted of persistent cough,
sputum production or dyspnoea (Symptoms
+spirometry);
8. Respiratory symptom deﬁnition only (Symptoms only).
The presence of spirometry for inclusion in the algo-
rithm was based on the existence of a record of a spe-
ciﬁc value or a Read code for spirometry rather than an
examination of the actual value. We were able to assess
the interpretation of spirometry in the subset of patients
who had ﬂow volume loops or clinic letters attached and
where the actual forced expiratory volume in 1 s and
forced vital capacity values were available in CPRD.
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Study population
The study population consisted of a random sample of
individuals selected from all participants registered in
CPRD with the cohort entry being on or after 1 January
2004. At cohort entry, people included had to be: over
35 years old, with at least 1 year historical data, and a
possible diagnosis of COPD deﬁned as evidence of
having ever smoked and a record of at least one speciﬁc
or possible COPD code or respiratory symptoms suggest-
ive of COPD. The presence of the algorithms was ascer-
tained during a period between patient cohort entry
and 31 December 2012. Patients had to be alive within
4 months of the last collection date of CPRD data for
the January 2013 data build for inclusion in the analysis
so that CPRD could access their medical records and
additional information. For the main analysis, a patient
could contribute to one algorithm only. It was possible
for an individual to be eligible for more than one algo-
rithm depending on the codes used in their medical
record over the study period. Individuals were randomly
selected from the algorithm with the fewest number of
participants ﬁrst and then removed from the cohort so
that they could not be selected for another algorithm.
CPRD mailed a short, structured questionnaire to GPs
in charge of randomly selected patients requesting con-
ﬁrmation of COPD status as well as any available speciﬁc
information from the individual’s medical record includ-
ing spirometry printouts and hospital respiratory out-
patient letters (see online supplementary material).
Data were ‘twice encrypted’ within CPRD to ensure ano-
nymity, ﬁrst between practices and CPRD and second
from CPRD to researchers. In the questionnaire, the GP
was asked whether or not the patient had a diagnosis of
COPD, what that diagnosis was based on, whether or not
the patient had seen a respiratory physician and if they
had, whether there were any other respiratory diagnoses.
A pilot set of 20 questionnaires were sent to GPs to
assess the quality of the questionnaire. In total, 951 ques-
tionnaires were sent out, assuming an 80% response
rate.
Primary outcome
The primary outcome was identiﬁcation of a diagnosis
of COPD according to the predeﬁned eight algorithms.
The gold standard for the diagnosis of COPD was the
decision made after respiratory physicians independently
reviewed the evidence from the GP (questionnaire
response with or without additional evidence). Where
they did not agree, a third independent physician
decided. Additionally, GP diagnosis of COPD was vali-
dated in a subset of patients where the GP provided sup-
portive information including spirometry printouts and
hospital letters. This also allowed a review of spirometry
interpretation in some cases. Although we used two
respiratory physicians independently as the gold stand-
ard for diagnosing COPD, this was done by reviewing
the questionnaire sent to the GP (see appendix) as well
as any additional information the GP sent which
supported that diagnosis. This supporting information
ranged from free text in the GP database to spirometry
printouts done in the GP surgery to letters from second-
ary care. Therefore, we were not solely relying on infor-
mation from secondary care to make the diagnosis
unless the GP decided to share that information. In this
way, we were able to include and validate the diagnosis
of COPD in people who were not seen in secondary
care.
Analysis
The primary analysis focused on the accuracy of identiﬁ-
cation of a COPD diagnosis in each of the predeﬁned
algorithms as deﬁned by the PPV, that is, the proportion
of ‘true positives’ (individuals with COPD) in each algo-
rithm as determined by the gold standard. In addition,
within each algorithm, where additional information was
provided (lung function, hospital clinic letters), we cal-
culated the accuracy of the GP diagnosis of COPD rela-
tive to the gold standard. This allowed a review of
spirometry interpretation in some cases.
We assessed the impact of commonly occurring
comorbidities on the accuracy of the prespeciﬁed algo-
rithms stratifying for cardiovascular comorbidity, previ-
ous asthma diagnosis, smoking status and, where
possible, GOLD staging of airﬂow limitation severity.13
Cardiovascular comorbidity included angina, history of
myocardial infarction, previous coronary artery bypass
graft/percutaneous coronary intervention or heart
failure, but not hypertension due to its lack of overlap of
symptoms that could mimic COPD. All covariates for
stratiﬁcation analysis were derived from information
available up to cohort entry.
As a post hoc analysis, individuals were eligible to be
placed into multiple algorithms where possible, and the
PPV was calculated for all individuals who had a speciﬁc
COPD code compared with those with a speciﬁc COPD
code and additional information (either spirometry or a
COPD medication).
Assessment of possible trends in COPD diagnosis
recording were also evaluated, including temporal
trends in codes used and diagnostic speciﬁcity from
2004 to 2011. In addition, we compared our speciﬁc
COPD codes with those recommended for use by QOF
(see online supplementary material)14 15: H31%
(excluding H3101 (smoker’s cough), H31y0 (chronic
tracheitis) and H3122 (acute exacerbation of COPD))
and H32% H36-H3z (excluding H3y0 and H3y1).
Sample size calculation
Our sample size for each algorithm was chosen to
achieve accuracy of the true positives or the PPV ±0.08
based on the reviewing physician’s judgement as the
gold standard. Assuming an estimated PPV of 0.85 for
any one algorithm, we required a sample of at least 77
individuals in each algorithm to achieve the desired
accuracy (95% CI ±0.08). All analyses were performed
using STATAV.13.
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RESULTS
Nine hundred and ﬁfty-one questionnaires were sent to
GPs (see ﬁgure 1 for patient selection). Of those, 738
(77.6%) were returned, 704 (74.0%) met quality control
standards and were not duplicates and 696 (73.2%)
could be included in the ﬁnal analysis (8 had ‘uncer-
tain’ COPD diagnosis and no supporting documentation
and were therefore excluded).
Among those included in the ﬁnal analysis, additional
evidence for the diagnosis of COPD was available for
272 patients. This represented 39.1% of the total study
population, or 67.7% of the 402 patients with a con-
ﬁrmed COPD diagnosis in the study.
Overall, irrespective of the qualifying algorithm, 402
patients (57.8%) were considered to have a diagnosis of
COPD based on the reviewing physician judgement.
Table 1 shows the characteristics of the 696 patients
included in the ﬁnal analysis who were considered to
possibly have COPD based on the inclusion criteria. On
average, patients were in their mid-60s to early 70s across
all algorithms. Approximately two-thirds of them were
current smokers and one-quarter had a history of
asthma. Generally, there were fewer patients with
supporting information and cardiovascular comorbidity
in the less speciﬁc algorithms (4–8).
The number of patients diagnosed with COPD con-
ﬁrmed by the gold standard and the PPV for each algo-
rithm is given in table 2. The PPV was greatest for
algorithms 1–4. Further data are available in the online
supplementary material regarding the effect of
comorbidities (see online supplementary table S1),
smoking status (see online supplementary table S2) and
GOLD staging (see online supplementary table S3) on
the performance of each algorithm.
In a subset of 272 patients where additional evidence
was available (in the form of spirometry printouts or
hospital outpatient letters), we assessed accuracy of GP
diagnosis of COPD. Overall, the PPV in this group was
95% (91.1–97.2). This is broken down by the algorithm
in table 3. While the presence of supporting evidence
improved the PPV in each group, algorithms 1–4 were
still most accurate.
Post hoc analysis
We repeated the analysis allowing individuals to be put
into more than one algorithm and tested the PPV of
Figure 1 Study population
(COPD, chronic obstructive
pulmonary disease; GP, general
practitioner).
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Table 1 Characteristics of the 696 patients included in the final study analysis
Algorithm
COPD Code
+spirometry+COPD
medication
COPD Code
+spirometry
COPD Code
+COPD
medication
COPD Code
only
Bronchitis
+COPD
medication
Bronchitis
only
Symptoms
+spirometry
Symptoms
only
Number of individuals (%) 85 (100) 79 (100) 88 (100) 89 (100) 98 (100) 84 (100) 83 (100) 90 (100)
Number (%) with
supporting info
46 (54.1) 44 (55.7) 48 (54.5) 40 (44.9) 32 (32.7) 18 (21.4) 30 (36.1) 14 (15.6)
Mean age (SD) 68.7 (11.3) 68.3 (11.7) 71.8 (10.5) 71.1 (10.4) 68.5 (13.1) 67.8 (13.4) 65.9 (11.9) 63.4 (14.1)
Male (%) 45 (52.9) 41 (51.9) 40 (45.5) 44 (49.4) 31 (31.6) 29 (34.5) 43 (51.8) 47 (52.2)
Current smoker (%) 49 (57.7) 50 (63.3) 55 (62.5) 47 (52.8) 66 (67.4) 61 (72.6) 48 (57.8) 58 (64.4)
GOLD stage (n=465)*
1 13 (16.3) 14 (18.0) 13 (15.9) 16 (20.5) 17 (28.8) 13 (35.1) 8 (20.0) 4 (36.4)
2 43 (53.8) 48 (61.5) 41 (50.0) 46 (59.0) 31(52.5) 13 (35.1) 22 (55.0) 5 (45.5)
3 18 (22.5) 13 (16.7) 22 (26.8) 12 (15.4) 9 (15.3) 8 (21.6) 8 (20.0) 2 (18.2)
4 6 (7.5) 3 (3.9) 6 (7.3) 4 (5.1) 2 (3.4) 3 (8.1) 2 (5.0) 0 (0.0)
History of cardiovascular
disease
20 (23.5) 22 (27.8) 17 (19.3) 18 (20.2) 20 (20.4) 17 (20.2) 14 (16.9) 9 (10.0)
History of asthma 18 (21.2) 20 (25.3) 16 (18.2) 15 (16.9) 27 (27.6) 23 (27.4) 19 (22.9) 23 (25.6)
Mean BMI (SD) (n=575) N=83
27.5 (5.4)
N=78
26.7 (5.8)
N=86
26.4 (4.7)
N=87
27.8 (5.4)
N=98
27.4 (5.1)
N=85
28.1 (5.0)
N=41
27.1 (4.5)
N=17
27.6 (4.7)
*GOLD staging was ascertained from CPRD records or from supplementary information provided by GPs.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; GOLD, Global initiative for Chronic Obstructive Lung Disease; GP, general
practitioner.
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COPD by the algorithm relative to the gold standard
where individuals were identiﬁed using only the pres-
ence of a speciﬁc COPD code (n=457) the PPV was
identical to if they had a COPD code and evidence
either in the form of spirometry or COPD medication
prescription (n=454); PPV 83% (79–86) for both. In the
majority of cases, where a speciﬁc COPD code had been
assigned, there was additional evidence. Only three indi-
viduals had a speciﬁc COPD code with no additional
evidence.
DISCUSSION
We tested the accuracy of eight different algorithms for
identifying COPD within the CPRD among patients with
suspected COPD (eg, >35 years of age, smoking history
and recording of respiratory symptoms or COPD codes).
The physician reviewer’s consensus was the gold stand-
ard. The best performing algorithm allowed an accurate
ascertainment of 90% of patients as diagnosed with
COPD. This consisted of a combination of a speciﬁc
COPD code, more than one prescription of a COPD
medication and spirometry (PPV 89.4, 95% CI 80.7 to
94.5). The worst performing algorithm was represented
by the presence of respiratory symptoms only (PPV 12.2,
95%CI 6.8 to 20.9). We found that any algorithm con-
taining a speciﬁc COPD code performed better than
those without (algorithms 1–4). In a post hoc analysis,
where we allowed individuals to populate more than one
algorithm, we established that the use of additional
information such as spirometry or medications in an
algorithm to a speciﬁc COPD Read code alone did not
increase the PPV. This suggests that the presence of a
speciﬁc COPD Read code alone is sufﬁcient to accur-
ately identify patients with COPD from the database.
Some study protocols require the presence of obstructive
spirometry for identiﬁcation of patients with COPD;
however, this study demonstrates that it may be unneces-
sary. This is particularly important as certain groups of
individuals are less likely to have spirometry, namely
Table 2 The positive predictive value (PPV) and proportion of patients diagnosed with chronic obstructive pulmonary
disease (COPD) within each algorithm
Algorithm
Number of questionnaires
sent out (n=951)
Number evaluable
returned (n=696) (%)
Number with
confirmed COPD PPV and 95% CI
COPD Code+spirometry
+COPD medication
119 85 (71.4) 76 89.4, 80.7 to 94.5
COPD Code+spirometry 119 79 (66.4) 67 83.8, 73.7 to 90.4
COPD Code+COPD
medication
119 88 (73.9) 77 87.5, 78.6 to 93.0
COPD Code only 119 89 (74.8) 77 86.5, 77.5 to 92.3
Bronchitis+COPD
medication
119 98 (82.4) 44 44.4, 34.8 to 54.5
Bronchitis only 119 84 (70.6) 26 29.5, 20.8 to 40.1
Symptoms+spirometry 119 83 (69.7) 37 43.5, 33.2 to 54.4
Symptoms only 118 90 (75.6) 11 12.2, 6.8 to 20.9
Table 3 Positive predictive value (PPV) by algorithm where evidence was available to assess GP compared with physician
diagnosis of chronic obstructive pulmonary disease (COPD)
Algorithm
Total number with
evidence (N=272)
Number of patients with COPD
confirmed by gold standard
(N=220)
Number with COPD
according to GP PPV and 95% CI
COPD Code
+spirometry+COPD
medication
46 46 46 100
COPD Code
+spirometry
44 35 33 94.3, 82.4 to 98.9
COPD Code+COPD
medication
48 43 41 95.3, 82.4 to 98.9
COPD Code only 40 34 33 97.1, 80.2 to 99.6
Bronchitis+COPD
medication
32 21 19 90.5, 66.0 to 97.9
Bronchitis only 18 12 11 91.7, 49.9 to 99.2
Symptoms+spirometry 30 21 20 95.2, 69.1 to 99.4
Symptoms only 14 8 6 75.0, 27.6 to 95.9
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women and patients <50 and >80 years of age.8 This is
also important as the minimal precision lost by not
including spirometry and medications in the algorithm
allows an increase in the number of individuals who can
potentially be included in a study. Using the whole of
CPRD, we identiﬁed individuals with COPD using a spe-
ciﬁc COPD code only compared with a speciﬁc code
plus medication and spirometry and found an increase
in the potential sample size for a study of 10% using a
speciﬁc COPD code only.
One of the advantages of this study was our ability to
investigate the accuracy of algorithms when identifying
patients with COPD within the CPRD, and the accuracy
of the actual GP diagnosis of COPD. When validating
the GP diagnosis of COPD with a respiratory physician’s
diagnosis as the gold standard based on extra evidence
provided by the GP, there was improved accuracy (PPV)
across all algorithms, with algorithms 1–4 again perform-
ing best. This suggests that additional evidence is col-
lected when the GP is reasonably certain that the
patient has COPD. There was good concordance
between the GP’s and the respiratory physician’s diagno-
sis, suggesting that respiratory consultant validation is
not always needed. Where there was disagreement, this
was usually because lung function did not meet the cri-
teria for COPD.
We found that the diagnostic accuracy of COPD
decreased across all algorithms when patients also had a
diagnosis of cardiovascular disease or asthma (see
online supplementary table S1). When patients had a
concomitant diagnosis of asthma, the presence of spir-
ometry was particularly important to improve accuracy
of COPD diagnosis. This was predominantly due to the
fact that spirometry had been misinterpreted. However,
stratiﬁcation led to smaller sample sizes, which could
have impacted the precision of estimates. Unsurprisingly,
the addition of the use of any inhaled COPD medication
to the algorithm did not improve precision, most likely
due to the overlap in medications used to treat asthma
and COPD (see online supplementary material). The
algorithm accuracy was not affected by smoking status
(current vs ex-smoker; see online supplementary table
S2). We only included current or former smokers in our
analysis, and cannot be sure of the validity of the results
in a patient who has never smoked. Certainly in the UK,
the majority of COPD is related to tobacco smoking and
we hypothesised that ﬁxed airﬂow obstruction in a non-
smoker would most likely be due to chronic asthma.
When considering the severity of COPD by GOLD clas-
siﬁcation, algorithms 2 and 3, that is, a speciﬁc COPD
code and spirometry or COPD medications, had the
greatest accuracy for patients with mild disease (GOLD
stage 1; see online supplementary table S3). The PPV
increased with increasing disease severity. It increases
with disease prevalence, and the prevalence of COPD
increased by moving from algorithm 8 to algorithm 1.
We considered the timing of diagnosis in view of an
increased uptake of spirometry in primary care in more
recent years and changes in QOF requirements over
time during our study period (see online supplementary
table S4). We found that algorithms 1–4 still had the
greatest accuracy, but the PPV estimates were better for
the post 2008 period than the pre 2008 period (see
online supplementary material). Non-speciﬁc bronchitis
codes and symptom codes were more likely to be used
before 2008 rather than after 2008. This may require
consideration when developing retrospective cohorts for
analysis and otherwise suggests that QOF has had a posi-
tive effect on the consistency of codes used for COPD
diagnoses. However, our codes were more speciﬁc than
QOF codes and some of the codes included in QOF
were not included in our speciﬁc COPD codelist, but
were included in the non-speciﬁc bronchitis codes.
While we cannot comment on the accuracy of QOF
codes, it is important to highlight that some QOF codes
are not disease speciﬁc and may not be a good way of
identifying patients with COPD from electronic health
records as inevitably people without COPD will be
included. It is also important to highlight that Read
codes change over time with new codes being added
and some removed, and this needs consideration when
identifying people with COPD.
There are limited COPD validation studies in elec-
tronic health records published in the literature with
which we can compare our study. Soriano et al4 validated
COPD in the GPRD in 2001, when OXMIS codes were
still in use. A Swedish study using a Swedish inpatient
registry used International Classiﬁcation of Diseases
(ICD)-9 and ICD-10 codes and identiﬁed patients with
COPD with similar accuracy.16 A Canadian study in the
Canadian primary care sentinel surveillance network
used algorithms to identify several long-term conditions
and also had a PPV similar to ours for COPD.17
However, all of these studies used different codes, algo-
rithms and databases.
Our analysis has several limitations. We appreciate that
using the gold standard of a GP questionnaire and
respiratory physician review is not perfect as when asked
about whether or not a speciﬁc patient has a certain
diagnosis, the GP is most likely to simply look in the
electronic health record and see if that diagnosis has
been recorded. However, there is no alternative. The
overall response rate for this study was acceptable
(77.6%), while the proportion of questionnaires accom-
panied by additional evidence allowing for adjudication
was rather low. We used PPV in this study as the measure
of accuracy to allow us to determine the probability that
a patient had COPD from their electronic health record.
The PPV is correlated with disease prevalence, and
although it is strongly related to speciﬁcity, the actual
estimates of speciﬁcity, sensitivity and negative predictive
value cannot be determined from our data. Further, GP
practices are self-selecting with respect to their contribu-
tion to CPRD; however, those practices appear to be rep-
resentative of the UK population. Very few patients
within contributing practices refuse to participate at an
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individual level and this is not thought to bias the
results. While CPRD is representative of the general
population, as with all validation studies that require a
response, we cannot be sure that our sample is represen-
tative of GPs who have not responded, although there is
unlikely to be any difference. The amount of missing
data among the responding questionnaires was low, sug-
gesting reasonable data quality. One of the other limita-
tions of this study is that patients had to be alive to be
included; however, it is unlikely that coding would be
different for individuals who are no longer alive.
The algorithm that consisted of a speciﬁc COPD code,
COPD medication and spirometry had the highest PPV;
however, the PPV was almost as high when a speciﬁc
COPD code alone was used. The poorest performing
algorithms were those that involved bronchitis codes or
respiratory symptoms; we would not recommend using
these algorithms to identify patients with COPD. In con-
clusion, we have shown that the presence of a speciﬁc
COPD Read code alone is sufﬁcient to identify patients
with COPD from electronic health records such as
CPRD. Minimal precision lost by not including spirom-
etry and medications in the algorithm allows an increase
in the number of individuals who can potentially be
included in a study by up to 10%. However, by not
including spirometry in the deﬁnition, the ability to
stage COPD according to GOLD stages may not be pos-
sible for all patients with COPD included in a study.
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